Loading
Led EPCORE NHL-1, the trial that established the subcutaneous bispecific epcoritamab for relapsed large B-cell lymphoma.
Catherine Thieblemont (Hôpital Saint-Louis, Paris) was principal investigator of EPCORE NHL-1, the pivotal trial showing the subcutaneous CD3xCD20 bispecific epcoritamab produces deep, durable responses in relapsed or refractory large B-cell lymphoma, leading to its approval. She has led LYSA trials in marginal zone and elderly DLBCL and co-chairs the EPCORE programme moving bispecifics into earlier lines.
CD20 x CD3 bispecifics gave patients whose lymphoma has failed CAR-T, or who cannot access it, an effective off-the-shelf treatment that can be started within days. Epcoritamab and glofitamab are now standard third-line options and are moving into earlier lines and combinations. They do not yet replace CAR-T, whose remissions appear more durable.
Chemotherapy-free cellular therapy for follicular lymphoma that has stopped responding, with a toxicity profile mild enough that the treatment is deliverable outside the largest centres.
A clean example of a progression-free survival benefit that did not become a survival benefit. Lenalidomide maintenance did not become standard practice after this trial, and the figures are the reason.
One of the few maintenance strategies in lymphoma that improved overall survival rather than only progression-free survival, and the reason three years of rituximab became standard after autologous transplantation in mantle cell lymphoma.
Shares CD3, CD20, Bispecific antibodies, T-cell engagers (bispecific) and the tags lymphoma, bispecific.
Shares REMARC, Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line R-CHOP, CD20, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tags lymphoma, lysa.
Shares CD20, Diffuse large B-cell lymphoma and the tags lymphoma, lysa.
Shares Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial, ELARA, CD20, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tag lymphoma.
Shares CD3, Bispecific antibodies, T-cell engagers (bispecific) and the tag bispecific.
Shares CD3, CD20, Bispecific antibodies, T-cell engagers (bispecific).
Shares CD20, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Diffuse large B-cell lymphoma and the tag lymphoma.
Shares CD3, Bispecific antibodies, T-cell engagers (bispecific) and the tag bispecific.